849672-60-2

Downstream Products

• 849671-97-2 2-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-N-methyl-5-oxocyclopent-1-ene-1-carboxamide 
• 849671-96-1 methyl 2-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-5-oxocyclopent-1-ene-1-carboxylate 
• 849671-94-9 (4R)-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-4-hydroxycyclopent-2-en-1-one 
• 849674-10-8 (4S)-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-4-hydroxycyclopent-2-en-1-one 
• 849674-09-5 (5S)-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-5-hydroxycyclopent-2-en-1-one 
• 849671-92-7 (5R)-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-5-hydroxycyclopent-2-en-1-one 
• 849674-08-4 (5S)-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-5-methylcyclopent-2-en-1-one 
• 849671-91-6 (5R)-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]-5-methylcyclopent-2-en-1-one 
• 849672-12-4 (3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl)-N-methylpyrrolidine-1-carboxamide 
• 849671-86-9 3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-fluorophenyl) pyrrolidin-1-yl]cyclopent-2-en-1-one 

Relevant academic research and scientific papers

The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine

SAR studies on amides, ureas, and vinylogous amides derived from pyrrolidine led to the discovery of several potent hNK1 antagonists. One particular vinylogous amide (45b) had excellent potency, selectivity, pharmacokinetic profile, and functio

PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical f